Esperion Therapeutics ESPR Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's net income?
- Esperion Therapeutics (ESPR) reported net income of -$25.2M in Q1 2026.
- How has Esperion Therapeutics's net income changed year-over-year?
- Esperion Therapeutics's net income increased by 37.7% year-over-year, from -$40.46M to -$25.2M.
- What is the long-term trend for Esperion Therapeutics's net income?
- Over 3 years (2021 to 2024), Esperion Therapeutics's net income has grown at a -42.3% compound annual growth rate (CAGR), from -$269.11M to -$51.75M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.